|Treatments:||Chemotherapy, Radiation||Hospital:||Mount Vernon Cancer Centre|
Patients: This Phase I study involved 18 patients with locally advanced rectal cancer. Twelve patients were men, six were women, and the median age was 56.8 years.
Treatment: The treatment consisted of radiation therapy and two chemotherapeutic agents: capecitabine and oxaliplatin.
Toxicity: Grade 1-4 toxicities included diarrhea, lethargy, abdominal pain, and rectal pain.
Results: The median overall survival was not reported. Five patients had a complete response to treatment.
Support: Roche Laboratories provided "study support." Roche markets and/or manufactures capecitabine.
Correspondence: Antonius A. Miller